Cyclin E deregulation is an early event in the development of breast cancer
- 171 Downloads
Cyclin E has been shown to be overexpressed in some human breast cancers, however, data to support deregulation of cyclin E as an early event in human mammary tumor development is lacking. We analyzed surgical specimens from 183 patients with breast carcinomas and evaluated cyclin E expression in areas of invasive carcinoma, adjacent carcinoma in situ (CIS), and non-neoplastic breast parenchyma. Overexpression of cyclin E was seen in one-third of invasive carcinoma samples, one-third of the CIS component and nearly half of the non-neoplastic breast epithelial cells adjacent to carcinoma (44% vs. 33%, P ≤ 0.05). Nuclear labeling for cyclin E was highly concordant between areas of in invasive carcinoma, CIS and non-neoplastic breast epithelial cells from the same patient (P < 0.0001). Localization of cyclin E to the cytoplasm was seen in a small proportion of tumor samples. Our findings suggest that cyclin E deregulation is an early event in the progression from histologically benign mammary epithelial cells to invasive carcinoma and occurs through both overexpression and altered cellular localization.
KeywordsCyclin E Premalignant breast disease Breast cancer Cytoplasmic localization
The authors wish to thank Robyn Kuhn and Roland L. Bassett Jr. for their assistance with the statistical analysis. Supported by Texas Federation of Business and Professional Women and National Institutes of Health grant CA116199 (SPORE in Breast Cancer).
- 5.Ferreri AJ, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell’Oro S, Baldini L, Buffa R, Carboni N, Villa E et al (2001) Immunoreactivity for p27(KIP1) and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin’s lymphoma. Int J Cancer 94(4):599–604. doi: 10.1002/ijc.1509 PubMedCrossRefGoogle Scholar
- 8.Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3(2):222–225. doi: 10.1038/nm0297-222 PubMedCrossRefGoogle Scholar
- 17.Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64(9):3198–3208. doi: 10.1158/0008-5472.CAN-03-3672 PubMedCrossRefGoogle Scholar
- 20.Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G (2003) Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence. Br J Cancer 89(10):1920–1926. doi: 10.1038/sj.bjc.6601398 PubMedCrossRefGoogle Scholar
- 35.Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67(15):7212–7222. doi: 10.1158/0008-5472.CAN-07-0599 PubMedCrossRefGoogle Scholar